nach oben

International Cancer Conference Journal

Erschienen in:

14.03.2023 | Case Report - Diagnosis

Anti-Mi-2 antibody-positive lung cancer-associated polymyositis

verfasst von: Masafumi Shimoda, Yoshiaki Tanaka, Atsuo Taniguchi, Kozo Morimoto, Kozo Yoshimori, Ken Ohta

Erschienen in: International Cancer Conference Journal | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

After a 75-year-old man was diagnosed with lung cancer, proximal weakness and myalgia in the bilateral lower extremities developed, and the creatinine kinase (CK) level was elevated. The anti-Mi-2 antibody test was positive, muscle T2-weighted/fat-suppressed magnetic resonance imaging showed high intensity, and there were no skin lesions. Therefore, he was diagnosed with lung cancer-associated polymyositis (PM). The lung tumour shrank after chemotherapy, accompanied by gradual improvement of his PM-derived symptoms and CK level. Although positive anti-Mi-2 antibody tests rarely indicate PM and cancer, examining myositis-specific autoantibodies, including anti-Mi-2, should be considered if the CK level increases after a cancer diagnosis.

Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A (2005) Anti-Mi-2 antibodies. Autoimmunity 38(1):79–83CrossRefPubMed

Richards M, Garcia-De La Torre I, Gonzalez-Bello YC, Vazquez-Del Mercado M, Andrade-Ortega L, Medrano-Ramirez G, Navarro-Zarza JE, Maradiaga-Cecena M, Loyo E, Rojo-Mejia A, Gomez G, Seaman A, Fritzler MJ, Koenig M, Mahler M (2019) Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 58(9):1655–1661CrossRefPubMed

McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290–302CrossRefPubMed

Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6(2):108–119CrossRefPubMedPubMedCentral

Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259CrossRefPubMedPubMedCentral

Zhao Y, Su H, Yin X, Hou H, Wang Y, Xu Y, Li X, Zhang N, Sun W, Wei W (2023) Cancer associated autoantibodies in idiopathic inflammatory myopathies: a retrospective cohort from a single center in China. Med Clin (Barc) 160:10–16CrossRefPubMed

Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Danko K (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35(3):438–444PubMed

Tomii K, Kato T, Takahashi M, Noma S, Kobashi Y, Enatsu S, Okubo S, Kobayashi N, Kudoh S (2017) Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol 47(4):350–356CrossRefPubMed

Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28(6):913–921CrossRefPubMed

10.

Opinc AH, Makowska JS (2022) Update on malignancy in myositis-well-established association with unmet needs. Biomolecules 12(1):111CrossRefPubMedPubMedCentral

11.

Khamooshi P, Pavonm M, Kang-Yoonsun C, Viviana Reyes P, Augustine Mathew M (2022) A rare case of paraneoplastic dermatomyositis in a patient with metastatic endometrial cancer. Ann Intern Med Clin Cases 1:e220480CrossRef

12.

Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, Martel C, Masseau A, Meyer A, Terrier B, Guegan S, Verneuil L, Audia S, Livideanu CB, Hachulla E, Kahn JE, Lefevre G, Maurier F, Moulis G, Papo T, Dossier A, Descamps V, Salort-Campana E, Richard MA, Bergot E, Mortier L, Costedoat-Chalumeau N, Genot S, Perez F, Piette AM, Samson M, Schleinitz N, Zenone T, Lacoste M, de Boysson H, Madaule S, Rigolet A, Champtiaux N, Hervier B, Bouvier AM, Jooste V, Leonard-Louis S, Maisonobe T, Aouba A, Benveniste O, Bienvenu B, Allenbach Y, French Myositis Network (2020) Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 83(6):1759–1763CrossRefPubMed

13.

Nawata T, Kubo M, Oishi K, Murata Y, Oishi M, Okazaki Y, Omoto M, Okazaki Y, Kanda T, Kuwana M, Yano M (2019) A case of cancer-associated myositis with anti-Mi-2 antibody: false-positive anti-transcriptional intermediary factor 1-gamma antibody by commercial enzyme-linked immunosorbent assay. Int J Rheum Dis 22(7):1335–1339CrossRefPubMed

14.

Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, Mosca M, Vencovsky J, van Venrooij WJ, van Engelen BG (2006) Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 65(2):242–245CrossRefPubMedPubMedCentral

15.

Moll SA, Platenburg M, Platteel ACM, Vorselaars ADM, Janssen Bonas M, Kraaijvanger R, Roodenburg-Benschop C, Meek B, van Moorsel CHM, Grutters JC (2022) Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases. PLoS One 17(11):e0277007CrossRefPubMedPubMedCentral

Titel: Anti-Mi-2 antibody-positive lung cancer-associated polymyositis
verfasst von: Masafumi Shimoda
Yoshiaki Tanaka
Atsuo Taniguchi
Kozo Morimoto
Kozo Yoshimori
Ken Ohta
Publikationsdatum: 14.03.2023
Verlag: Springer Nature Singapore
Erschienen in: International Cancer Conference Journal / Ausgabe 3/2023
Elektronische ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-023-00601-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Anti-Mi-2 antibody-positive lung cancer-associated polymyositis

Abstract

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Symptom palliation with QUAD Shot radiation therapy to penile metastasis derived from descending colon cancer: a case report

An unusual case of a tibial metastasis as the first clinical presentation of a serous papillary carcinoma of the ovarian epithelial type of the testis

Correction to: COVID arm that appeared in the contralateral upper extremity after mRNA‑1273 booster inoculation

A surgical resection of hepatic granuloma mimicking intrahepatic cholangiocarcinoma: a case report

Abscopal effect of radiation in metastatic esophageal carcinoma: fourth reported case

Peritoneal and pulmonary tuberculosis following intravesical administration of Bacillus Calmette–Guérin for bladder cancer

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie